Inhibition of fgr reduces fibrosis
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsAmitava MUKHERJEE, Michael EPPERLY, Joel GREENBERGER
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for treating and preventing a disease or condition characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject in need thereof. The particular disease or condition can be fibrosis, specifically, radiation-induced fibrosis. The method for treating or preventing the disease or condition can include administering to the subject an effective amount of a composition that inhibits Fgr, a non-receptor tyrosine kinase.
Claims47
A method for treating or preventing radiation-induced fibrosis in a subject in need thereof, the method comprising:
- administering to the subject an effective amount of a composition that inhibits Fgr (a non-receptor tyrosine kinase).
(canceled)
(canceled)
(canceled)
The method of claim 17, wherein the disease or condition is mediated by Fgr.
(canceled)
(canceled)
The method of claim 17, wherein the composition that inhibits Fgr is TL02-59.
The method of claim 17, wherein the composition that inhibits Fgr comprises shRNA that interferes with Fgr expression;
- CRISPR for editing or knockout of Fgr;
- siRNA, antisense RNA, or nucleic acids that interfere with or prevent the transcription or translation of Fgr genes;
- antisense molecules comprising Fgr sequences;
- active sites that bind at least a portion of Fgr;
- interfering peptides;
- interfering nucleic acids;
- or a combination thereof.
(canceled)
A method for treating or preventing a disease or condition characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject in need thereof, the method comprising:
- administering to the subject an effective amount of a composition that inhibits Fgr.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of identifying a pharmacological compound for treating or preventing fibrosis in a subject in need thereof, the method comprising:
- a) obtaining a population of p16 or β-galactosidase (SA-β-gal) expressing senescent cells from the subject;
- b) identifying Fgr positive senescent cells;
- c) contacting the Fgr positive senescent cells with the pharmacological compound;
- and
- d) determining whether the pharmacological compound inhibits Fgr in the Fgr positive senescent cells.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.